Acumen Pharmaceuticals Inc. (ABOS) NASDAQ
$3.79 0.10 (2.71%)
Market Cap: $221.69M
As of 05/15/24 03:57 PM EDT. Market open.
Acumen Pharmaceuticals Inc. (ABOS)
NASDAQ
$3.79
0.10 (2.71%)
Market Cap: $221.69M
As of 05/15/24 03:57 PM EDT. Market open.
Add to Portfolio
acumen is forging a new path towards safe and effective treatments for alzheimer’s disease and other neurodegenerative diseases through our focus on the biology of toxic amyloid-beta oligomers. our founders pioneered seminal discoveries and methods to understand the role of toxic amyloid-beta oligomers (a?o) in synaptic dysfunction and neurodegeneration. these early insights have fostered ... read more
COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Full Time Employees
1
Address
.
PRICE CHART FOR ACUMEN PHARMACEUTICALS INC
From:
To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$3.74
Previous Close
$3.69
Days Range
$3.50 - $3.73
52 week range
$1.81 - $11.31
Volume
203,210
Avg. Volume (30 days)
224,288
Market Cap
$221.69M
Dividend Yield
-
P/E
-
Shares Outstanding
60,079,778
Open
$3.74
Previous Close
$3.69
Days Range
$3.50 - $3.73
52 week range
$1.81 - $11.31
Volume
203,210
Avg. Volume (30 days)
224,288
Market Cap
$221.69M
Dividend Yield
-
P/E
-
Shares Outstanding
60,079,778
FINANCIAL STATEMENTS FOR ACUMEN PHARMACEUTICALS INC
LOADING...
Open in: 
Open in:
INSIDER TRANSACTIONS FOR ACUMEN PHARMACEUTICALS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| OConnell Daniel Joseph | President and CEO | Jan 19, 2024 | Sale | $3.47 | 15,200 | 52,753 | 502,485 | Jan 19, 2024, 07:07 PM |
| Meisner Derek M | Chief Legal Officer & Corp Sec | Jan 19, 2024 | Sale | $3.48 | 8,933 | 31,048 | 108,867 | Jan 19, 2024, 07:06 PM |
| Zuga Matt | CFO & Chief Business Officer | Jan 18, 2024 | Sale | $3.70 | 4,242 | 15,717 | 211,445 | Jan 19, 2024, 07:05 PM |
| Siemers Eric | Chief Medical Officer | Jan 18, 2024 | Sale | $3.71 | 3,124 | 11,604 | 117,576 | Jan 19, 2024, 07:05 PM |
| Barton Russell | Chief Operating Officer | Jan 18, 2024 | Sale | $3.73 | 2,833 | 10,555 | 96,867 | Jan 19, 2024, 07:04 PM |
| Ives Jeffrey L. | Director | Aug 17, 2023 | Option Exercise | $0.75 | 41,949 | 31,519 | 39,149 | Aug 18, 2023, 06:31 PM |
| Ives Jeffrey L. | Director | Aug 17, 2023 | Sale | $6.49 | 41,949 | 272,334 | 0 | Aug 18, 2023, 06:31 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Jul 21, 2023 | Buy | $7.75 | 5,161,290 | 39,999,998 | 13,043,179 | Jul 25, 2023, 04:30 PM |
| Zuga Matt | CFO and Chief Business Officer | Dec 29, 2022 | Option Exercise | $1.19 | 50,000 | 59,500 | 76,187 | Jan 03, 2023, 05:23 PM |
| OConnell Daniel Joseph | President and CEO | Nov 30, 2021 | Option Exercise | $4.47 | 1,118 | 4,997 | 2,685 | Dec 02, 2021, 04:41 PM |
| Manning Paul B | 10% Owner | Jul 06, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 3,352,693 | Jul 08, 2021, 06:35 PM |
| Stalfort John A III | Director | Jul 06, 2021 | Buy | $16.00 | 35,000 | 560,000 | 172,324 | Jul 08, 2021, 06:17 PM |
| OConnell Daniel Joseph | President and CEO | Jul 06, 2021 | Option Exercise | $16.00 | 10 | 160 | 1,567 | Jul 08, 2021, 06:16 PM |
| OConnell Daniel Joseph | President and CEO | Jul 06, 2021 | Option Exercise | $4.47 | 35 | 156 | 1,577 | Jul 08, 2021, 06:16 PM |
| Hardie Robert D. | 10% Owner | Jul 06, 2021 | Buy | $16.00 | 312,500 | 5,000,000 | 3,352,693 | Jul 08, 2021, 06:15 PM |
| Hardie Robert D. | 10% Owner | Jul 06, 2021 | Buy | $16.00 | 750,000 | 12,000,000 | 3,951,156 | Jul 08, 2021, 06:14 PM |
| Fountain Nathan B | Director | Jul 06, 2021 | Buy | $16.00 | 6,250 | 100,000 | 6,250 | Jul 08, 2021, 06:13 PM |
| Sands Capital Ventures Discovery Fund III, L.P. | 10% Owner | Jul 06, 2021 | Buy | $14.88 | 450,000 | 6,696,000 | 3,417,075 | Jul 08, 2021, 05:21 PM |
| RA CAPITAL MANAGEMENT, L.P. | Director | Jul 06, 2021 | Buy | $16.00 | 1,875,000 | 30,000,000 | 7,881,889 | Jul 08, 2021, 04:32 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| OConnell Daniel Joseph | President and CEO | 01/19/2024 | 52,753 |
| Meisner Derek M | Chief Legal Officer & Corp Sec | 01/19/2024 | 31,048 |
| Zuga Matt | CFO & Chief Business Officer | 01/18/2024 | 15,717 |
| Siemers Eric | Chief Medical Officer | 01/18/2024 | 11,604 |
| Barton Russell | Chief Operating Officer | 01/18/2024 | 10,555 |
| Ives Jeffrey L. | Director | 08/17/2023 | 31,519 |
| Ives Jeffrey L. | Director | 08/17/2023 | 272,334 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 07/21/2023 | 39,999,998 |
| Zuga Matt | CFO and Chief Business Officer | 12/29/2022 | 59,500 |
| OConnell Daniel Joseph | President and CEO | 11/30/2021 | 4,997 |
| Manning Paul B | 10% Owner | 07/06/2021 | 5,000,000 |
| Stalfort John A III | Director | 07/06/2021 | 560,000 |
| OConnell Daniel Joseph | President and CEO | 07/06/2021 | 160 |
| OConnell Daniel Joseph | President and CEO | 07/06/2021 | 156 |
| Hardie Robert D. | 10% Owner | 07/06/2021 | 5,000,000 |
| Hardie Robert D. | 10% Owner | 07/06/2021 | 12,000,000 |
| Fountain Nathan B | Director | 07/06/2021 | 100,000 |
| Sands Capital Ventures Discovery Fund III, L.P. | 10% Owner | 07/06/2021 | 6,696,000 |
| RA CAPITAL MANAGEMENT, L.P. | Director | 07/06/2021 | 30,000,000 |
Load More Insider Transactions
FUNDS WITH A POSITION IN ACUMEN PHARMACEUTICALS INC
| Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 14,932,063 | 0.9% | No change | Other |
| GEODE CAPITAL MANAGEMENT, LLC | 285,139 | 0.00011% | 7.76% | Other |
| BLACKROCK INC. | 189,697 | 0.00002% | -23.54% | Other |
| D. E. SHAW & CO., INC. | 138,029 | 0.00046% | New | Other |
| BALYASNY ASSET MANAGEMENT L.P. | 63,949 | 0.00045% | 210.76% | Event Driven |
CHANGE IN SHARES OUTSTANDING FOR ACUMEN PHARMACEUTICALS INC
STOCK BUYBACKS FOR ACUMEN PHARMACEUTICALS INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
Load More
Period of Report: 03/31/2024
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
12/31/2023
3.10%
1Q
09/30/2023
10.29%
2Q
03/31/2023
45.79%
4Q
12/31/2022
46.12%
5Q
09/30/2022
47.67%
6Q
06/30/2022
47.69%
7Q
03/31/2022
47.78%
8Q
09/30/2021
56.30%
10Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR ACUMEN PHARMACEUTICALS INC
LOADING...